Author Correction: Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41421-021-00267-0

Correction to: Cell Discovery (2020) 6:96

10.1038/s41421-020-00235-0 Published online 22 December 2020

We apologize for the mistake of the author affiliation information. In the initial published version of this article¹, there was an omission in author affiliations. “University of the Chinese Academy of Sciences, Beijing 100049, China” needs to be added to the affiliation of Yuan Sun, Qingxing Wang, Xiaming Jiang and Gengfu Xiao as the author’s second affiliation. The correct information is as follows. This correction does not affect the description of the results or the conclusion of this work. Lei-Ke Zhang¹, Yuan Sun^1,2, Haolong Zeng³, Qingxing Wang^1,2, Xiaming Jiang^1,2, Wei-Juan Shang¹, Yan Wu¹, Shufen Li¹, Yu-Lan Zhang¹, Zhao-Nian Hao⁴, Hongbo Chen⁵, Runming Jin⁵, Wei Liu⁶, Hao Li⁶, Ke Peng¹, Gengfu Xiao^1,2. ¹State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 430071, China. ²University of the Chinese Academy of Sciences, Beijing 100049, China. ³Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. ⁴Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. ⁵Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. ⁶Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing 100071, China